# A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies

> **NCT03440437** · PHASE1,PHASE2 · TERMINATED · sponsor: **invoX Pharma Limited** · enrollment: 80 (actual)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer
- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** FS118
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03440437
- **Lead sponsor:** invoX Pharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-16
- **Primary completion:** 2024-06-21
- **Final completion:** 2024-06-21
- **Target enrollment:** 80 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03440437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03440437, "A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03440437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*